Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of the American College of Cardiology

• Publication date

  2014-03-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacc.2013.10.048PMID 24211500
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

  2012influential reference
• Promises of PAR-1 Inhibition in Acute Coronary Syndrome

  2012cited by this paper
• Special Articles: 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2012cited by this paper
• Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies.

  2012cited by this paper
• Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.

  2012cited by this paper
• Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.

  2012cited by this paper
• Use of Aspirin and Clopidogrel After Coronary Artery Bypass Graft Surgery

  2012cited by this paper
• Vorapaxar in the secondary prevention of atherothrombotic events.

  2012cited by this paper
• 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesi

  2011cited by this paper
• Enhanced Thrombin Generation After Cardiopulmonary Bypass Surgery

  2011cited by this paper
• ACCF/AHA Practice Guideline 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

  2011cited by this paper
• Circulation Editors' Picks: Most Read Articles in Cardiovascular Surgery and Transplantation

  2011cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.

  2011cited by this paper
• Aspirin Plus Clopidogrel Versus Aspirin Alone After Coronary Artery Bypass Grafting: The Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) Trial

  2010cited by this paper
• Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial.

  2010cited by this paper
• Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis

  2010cited by this paper
• Endoscopic versus Open Vein-Graft Harvesting in Coronary-Artery Bypass Surgery

  2010cited by this paper
• Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.

  2009cited by this paper
• Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.

  2009cited by this paper
• The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

  2009cited by this paper
• On-pump versus off-pump coronary-artery bypass surgery.

  2009cited by this paper
• Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery.

  2009cited by this paper
• Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge.

  2006cited by this paper
• Thrombin generation during reperfusion after coronary artery bypass surgery associates with postoperative myocardial damage

  2006cited by this paper
• Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial

  2004cited by this paper
• A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients.

  2003cited by this paper
• Functional and Biochemical Evaluation of Platelet Aspirin Resistance After Coronary Artery Bypass Surgery

  2003cited by this paper
• Aspirin and mortality from coronary bypass surgery.

  2002cited by this paper
• Early angiographic control of perioperative ischemia after coronary artery bypass grafting.

  2001cited by this paper
• EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION

  2001cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Cardiopulmonary bypass and activation of antithrombotic plasma protein C.

  1999cited by this paper
• Endothelial cell injury in cardiovascular surgery: atherosclerosis.

  1997cited by this paper
• Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis.

  1997cited by this paper
• Hypercoagulable States

  1997cited by this paper
• Endothelial cell injury in cardiovascular surgery.

  1996cited by this paper
• Long-term graft patency (3 years) after coronary artery surgery. Effects of aspirin: results of a VA Cooperative study.

  1994cited by this paper
• Hypercoagulable States

  1993cited by this paper
• Thrombin Production, Inactivation and Expression during Open Heart Surgery Measured by Assays for Activation Fragments Including a New ELISA for Prothrombin Fragment F1+2

  1993cited by this paper
• Immediate Postoperative Aspirin Improves Vein Graft Patency Early and Late After Coronary Artery Bypass Graft Surgery: A Placebo‐Controlled, Randomized Study

  1991cited by this paper
• Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells.

  1991cited by this paper

• Artificial intelligence-enabled electrocardiography from scientific research to clinical application

  2025cites this paper
• Stroke prevention strategies for cardiac surgery: a systematic review and meta‐analysis of randomized controlled trials

  2024influential citation
• Synthesis of 12-quinoline substituted andrographolide derivatives and their preliminary evaluation as anti-aggregation drugs

  2023cites this paper
• Effects of Heparin and Bivalirudin on Thrombin-Induced Platelet Activation: Differential Modulation of PAR Signaling Drives Divergent Prothrombotic Responses

  2021cites this paper
• Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar.

  2021cites this paper
• Synthesis of 3,15-Disuccinate-12-Coumarin Substituted Andrographolide Derivatives and Their Antiplatelet Aggregation Activities In Vitro

  2020cites this paper
• Magnolol, A Novel Antagonist of Thrombin and PAR-1, Inhibits Thrombin-Induced Connective Tissue Growth Factor (CTGF) Expression in Vascular Smooth Muscle Cells and Ameliorate Pathogenesis of Restenosis in Rats

  2020cites this paper
• PAR-1 Antagonists

  2019cites this paper
• Update on protease‐activated receptor 2 in cutaneous barrier, differentiation, tumorigenesis and pigmentation, and its role in related dermatologic diseases

  2019cites this paper
• Investigational drugs for the treatment of acute myocardial infarction: focus on antiplatelet and anticoagulant agents

  2018cites this paper
• Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside

  2018cites this paper
• Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial

  2017cites this paper
• Targeting PAR1: Now What?

  2017cites this paper
• Peri-procedural use of anticoagulants in radiology: an evidence-based review

  2017cites this paper
• Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome

  2017cites this paper
• Safety and efficacy of vorapaxar in secondary prevention of atherosclerotic disease: A meta-analysis of randomized control trials.

  2017cites this paper
• Postoperative thrombocytopenia: why you should consider antiplatelet therapy?

  2017cites this paper
• Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease

  2017influential citation
• Platelet Counts and Postoperative Stroke After Coronary Artery Bypass Grafting Surgery

  2017cites this paper
• Role of Vorapaxar After Coronary Revascularization.

  2016cites this paper
• Low platelet activity predicts 30 days mortality in patients undergoing heart surgery

  2016cites this paper
• Vein graft failure: from pathophysiology to clinical outcomes

  2016cites this paper
• Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar

  2016cites this paper
• Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.

  2016cites this paper
• Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction

  2016cites this paper
• The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications.

  2016cites this paper
• Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition

  2016cites this paper
• Novel antithrombotic agents 2 Clinical evidence for oral antiplatelet therapy in acute coronary syndromes

  2015cites this paper
• Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar

  2015cites this paper
• PAR 1 Receptor / Protein Interactions 1 From Multiple PAR 1 Receptor / Protein Interactions to their Multiple Therapeutic Implications

  2015cites this paper
• Review of vorapaxar for the prevention of atherothrombotic events

  2015influential citation
• From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications.

  2015cites this paper
• Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives.

  2015cites this paper
• Vorapaxar in the secondary prevention of atherothrombosis

  2015cites this paper
• Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery

  2015cites this paper
• Protease‐activated receptors and their biological role – focused on skin inflammation

  2015cites this paper
• Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.

  2015cites this paper
• Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.

  2015cites this paper
• Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.

  2015cites this paper
• Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials

  2015cites this paper
• Novel antiplatelet agents in acute coronary syndrome

  2015cites this paper
• Vorapaxar in Atherosclerotic Disease Management

  2015cites this paper
• PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact

  2015cites this paper
• Vorapaxar in patients undergoing coronary artery bypass grafting: insights from a subgroup analysis.

  2014influential citation
• Vorapaxar: First Global Approval

  2014cites this paper
• Antithrombotic drugs.

  2014cites this paper
• Vascular Health and Risk Management Dovepress Unmet Needs in the Management of Acute Myocardial Infarction: Role of Novel Protease- Activated Receptor-1 Antagonist Vorapaxar

  year unknowncites this paper